INSTITUT GUSTAVE ROUSSY - France 

Ranking results:

Past rankings:

2020
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
2019
Criterium:Position:
Overall Score:900-1000
Total Project Funding per Partner:500-600
Total Number of Projects:> 1000
2018
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Networking Rank (Reputation):900-1000
2015
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2012
Criterium:Position:
Overall Score:400-500
Total Project Funding per Partner:300-400
Total Number of Projects:65
Total Project Funding:400-500
Networking Rank (Reputation):500-600
Networking Rank (Reputation):500-600
Partner Constancy:46
Project Leadership Index:75
Diversity Index:18
2011
Criterium:Position:
Overall Score:800-900
Total Project Funding per Partner:200-300
Total Number of Projects:200-300
Total Project Funding:100-200
Networking Rank (Reputation):200-300
Partner Constancy:100-200
Project Leadership Index:600-700
Diversity Index:> 1000
2009
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:700-800
Total Number of Projects:> 1000
Total Project Funding:600-700
Networking Rank (Reputation):> 1000
Partner Constancy:600-700
Project Leadership Index:500-600
Diversity Index:> 1000
2008
Criterium:Position:
Overall Score:400-500
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:600-700
Project Leadership Index:500-600
Diversity Index:500-600
2007
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:300-400
Total Number of Projects:600-700
Total Project Funding:400-500
Networking Rank (Reputation):> 1000
Partner Constancy:400-500
Project Leadership Index:400-500
Diversity Index:> 1000

Ranking timeline:

Project Participation Performance(2010-01-01 - 2024-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 41
As coordinator: 3
As participant: 35
Sole participant: 3
Coordinator / Participant Ratio: 0.09*

*Ratio includes only projects with > 2 partners

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2023 0 22.039.355 859.992 2
2022 6.718.019 11.055.661 3.475.158 2 2
2021 0 8.897.709 140.942 3
2020 0 28.999.948 851.989 3
2019 14.994.551 6.999.989 2.644.625 1 1
2018 0 12.436.859 540.750 1
2017 0 16.523.625 1.086.240 3
2016 1.500.000 0 1.500.000 1
2015 0 7.476.725 262.876 2
2013 2.998.355 11.662.081 1.517.283 1 2
2012 268.555 25.088.618 2.270.829 1 5
2011 0 63.192.794 4.425.298 11
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:Projects [No]:
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM10
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE9
KAROLINSKA INSTITUTE7
UNIVERSITY OF BIRMINGHAM7
INSTITUT CURIE6
STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS6
UNIVERSITY COLLEGE LONDON6
CHARITE UNIVERSITAETSMEDIZIN BERLIN5
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL5
UNIVERSITA DEGLI STUDI DI TORINO5
UNIVERSITY OF CAMBRIDGE5
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM4
DEUTSCHES KREBSFORSCHUNGSZENTRUM4
FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI4
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALLHEBRON4
ST ANNA KINDERKREBSFORSCHUNG4
THE UNIVERSITY OF MANCHESTER4
ACADEMISCH ZIEKENHUIS LEIDEN3
COMMISSARIAT A L'ENERGIE ATOMIQUE3
EUROPEAN CANCER ORGANISATION3
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III3
GSF FORSCHUNGSZENTRUM FUER UMWELT UND GESUNDHEIT3
INSTITUT JULES BORDET3
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER3
ISTITUTO EUROPEO DI ONCOLOGIA3
ISTITUTO GIANNINA GASLINI3
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI3
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN3
OSLO UNIVERSITETSSYKEHUS HF3
PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV3
REGION HOVEDSTADEN3
SIOP EUROPE3
STICHTING KATHOLIEKE UNIVERSITEIT3
UNICANCER3
UNIVERSITAET ZUERICH3
UNIVERSITAETSKLINIKUM ESSEN3
UNIVERSITY OF LEEDS3
UNIVERSITY OF NEWCASTLE UPON TYNE3
ACADEMISCH ZIEKENHUIS GRONINGEN2
ALLEANZA CONTRO IL CANCRO2
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS2
ASSUTA MEDICAL CENTERS2
AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO2
BELGIAN NUCLEAR RESEARCH CENTRE2
CENTRE ANTICANCEREUX LEON BERARD2
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE2
CONSIGLIO NAZIONALE DELLE RICERCHE2
DANISH CANCER SOCIETY2
DEPARTMENT OF HEALTH2
EBERHARD KARLS UNIVERSITAET TUEBINGEN2
ENTE PER LE NUOVE TECNOLOGIE L'ENERGIA E L'AMBIENTE2
EUROPEAN MOLECULAR BIOLOGY LABORATORY2
F HOFFMANNLA ROCHE2
GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG GAB O2
GBG FORSCHUNGS2
GESELLSCHAFT FUER SCHWERIONENFORSCHUNG MBH2
GROUPEMENT EUROPEEN D INTERET ECONOMIQUE ORGANISATION OF EUROPEAN CANCER INSTITUTES OECI2
INNOVATIVE THERAPIES FOR CHILDREN WITH CANCER ASSOCIATION2
INSTITUT CATALA D'ONCOLOGIA2
INSTITUT DE RADIOPROTECTION ET DE SURETE NUCLEAIRE2
INSTITUTE OF CANCER RESEARCH ROYAL CANCER HOSPITAL2
INTEGRATED SYSTEMS ENGINEERING2
ISTITUTO ORTOPEDICO RIZZOLI2
KATHOLIEKE UNIVERSITEIT LEUVEN2
KLINIKUM DER UNIVERSITAET ZU KOELN2
LEIDEN UNIVERSITY MEDICAL CENTER2
MASARYKOVA UNIVERZITA2
MEDICAL RESEARCH INFRASTRUCTURE DEVELOPMENT AND HEALTH SERVICES FUND BY THE SHEBA MEDICAL CENTER2
MEDIZINISCHE UNIVERSITAET WIEN2
MEDIZINISCHE UNIVERSITAT INNSBRUCK2
PHILIPPS UNIVERSITAET MARBURG2
QUEEN MARY AND WESTFIELD COLLEGE UNIVERSITY OF LONDON2
RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU2
SARCOMA PATIENTS EURONET EV2
SEMMELWEIS EGYETEM2
SERVICIO ANDALUZ DE SALUD2
STATE INSTITUTION RESEARCH CENTER FOR RADIATION MEDICINE OF THE ACADEMY OF MEDICAL SCIENCES OF UKRAINE2
STICHTING ANTONI VAN LEEUWENHOEK ZIEKENHUIS2
STOCKHOLM UNIVERSITET2
STUDIECENTRUM VOOR KERNENERGIE2
TECHNISCHE UNIVERSITAET MUENCHEN2
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE2
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD2
THE CHRISTIE NHS FOUNDATION TRUST2
THE LEEDS TEACHING HOSPITALS NATIONAL HEALTH SERVICE TRUST2
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA2
THE ROYAL MARSDEN NATIONAL HEALTH SERVICE TRUST2
THE UNIVERSITY OF NOTTINGHAM2
UNIVERSITA DEGLI STUDI DI MILANO BICOCCA2
UNIVERSITA DEGLI STUDI DI PADOVA2
UNIVERSITA DEGLI STUDI DI PAVIA2
UNIVERSITA DEGLI STUDI DI TRENTO2
UNIVERSITAET BERN2
UNIVERSITATSKLINIKUM ERLANGEN2
UNIVERSITE PARIS CITE2
UNIVERSITY COLLEGE CORK NATIONAL UNIVERSITY OF IRELAND CORK2
UNIVERSITY OF AARHUS2
UPPSALA UNIVERSITET2
VRIJE UNIVERSITEIT BRUSSEL2
WESTFAELISCHE WILHELMSUNIVERSITAET MUENSTER2

Constancy:

Total number of partners: 578
Partner loyalty:
Frequent Partner: (> 2 projects): 158
Rare Partner: 420
Frequent / Rare Partner Ratio: 0.38

Project overview:

Start dateProjectacronymrolefundingpartners
2023-01-01Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe EUonQoLparticipant10.607.31127
2023-01-01An innovative non-contact and harmless screening modality set to change the course of breast cancer detection and patient monitoring ThermoBreastparticipant11.432.04417
2022-12-01Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception. PREVALUNG EUcoordinator6.521.31212
2022-11-01Data-driven cancer genome interpretation for personalised cancer treatment CGI-Clinicsparticipant9.257.50817
2022-10-01Closing the European gap towards a large scale ex vivo platelet production built upon a silk-based scaffold bioreactor SilkPlateletparticipant1.798.1535
2022-02-21Spermidine in hypertension: therapeutic potential and novel mechanisms SPeR-ToNEcoordinator196.7081
2021-05-01International Human Microbiome Coordination and Support Action IHMCSAparticipant1.999.37017
2021-02-01Building Data Rich Clinical Trials CCE_DARTparticipant5.999.41112
2021-01-01Twinning in Research and Education to improve survival in Childhood Solid Tumours in Lithuania TRELparticipant898.92810
2020-09-01Towards effective radiation protection based on improved scientific evidence and social considerations - focus on radon and NORM RadoNormparticipant18.000.00060
2020-01-014-IN THE LUNG RUN: towards INdividually tailored INvitations, screening INtervals, and INtegrated co-morbidity reducing strategies in lung cancer screening 4-IN THE LUNG RUNparticipant7.999.94910
2020-01-01Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation. NeutroCureparticipant2.999.99912
2019-06-01Health effects of cArdiac fluoRoscopy and MOderN radIotherapy in paediatriCs HARMONICparticipant6.999.98924
2019-01-01Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response. ONCOBIOMEcoordinator14.994.55118
2018-01-01International Randomized Study Comparing personalized, Risk-Stratified to Standard Breast Cancer Screening In Women Aged 40-70 MyPeBSparticipant12.436.85929
2017-12-01A Clinical Phase IIB trial with 2OHOA in patients with newly-diagnosed malignant glioma. CLINGLIOparticipant6.155.12512
2017-11-01Genetically engineered human pluripotent stem cells, functionalized silk-fibroin platforms and bio-inks: a novel solution for large-scale ex-vivo platelet production, transfusion and drug research SilkFUSIONparticipant2.998.5006
2017-01-01ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064 ITCC-P4participant7.370.00021
2016-12-01Resistance mechanisms to tyrosine kinase inhibitors in solid tumors TKI resistancecoordinator1.500.0001
2015-12-01Training Network for the Immunotherapy of Cancer IMMUTRAINparticipant3.627.52510
2015-09-01ALK Activation as a target of TRAanslational Science (ALKATRAS): Break free from cancer ALKATRASparticipant3.849.20023
2013-10-01EURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma EECparticipant5.697.83120
2013-06-01Mutanome Engineered RNA Immuno-Therapy MERITparticipant5.964.2505
2013-03-01WINTHERapeutics: development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutic decision and improve clinical outcome for cancer patients WINTHERcoordinator2.998.35511
2012-11-01Non-Invasive Optical Biopsy for Cancer Assessment using ultra high resolution Full-Field Optical Coherence Tomography CAReIOCAparticipant3.099.4815
2012-10-01Rational molecular Assessments and Innovative Drug Selection RAIDSparticipant5.999.64216
2012-09-01Circulating Tumor Cells TheRapeutic APheresis: a novel biotechnology enabling personalized therapy for all cancer patients CTCTRAPparticipant6.000.00012
2012-08-01Genetic epidemiological investigation into the association between endometriosis and cutaneous melanoma MELENDO2coordinator268.5551
2012-04-01Biomaterials for Tracheal Replacement in Age-related Cancer via a Humanly Engineered Airway BIOtracheaparticipant3.999.30013
2012-02-01Genome-based biomarkers leading to validated molecular diagnostic tests for response prediction in breast cancer RESPONSIFYparticipant5.990.19512
2011-12-01European Clinical trials in Rare Sarcomas within an integrated translational trial network EUROSARCparticipant5.953.83218
2011-12-01STRENGTHENING COOPERATION IN MOLECULAR BIOMEDICINE BETWEEN EU AND UKRAINE COMBIOMparticipant455.4993
2011-10-01Cardiovascular Risk from Exposure to Low-dose and Low-dose-rate Ionizing Radiation PROCARDIOparticipant2.998.38713
2011-10-01Cognitive and Cerebrovascular Effects Induced by Low Dose Ionising Radiation CEREBRADparticipant2.999.51712
2011-04-01Adaptive and innovative Radiation Treatment FOR improving Cancer patients treatment outcomE ARTFORCEparticipant5.994.71514
2011-02-01PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies PanCareSurFupparticipant5.993.69517
2011-01-01Determining (epi)genetic therapeutic signatures for improving lung cancer prognosis CURELUNGparticipant2.965.74911
2011-01-01European Network for the Study of Adrenal Tumours - Structuring clinical research on adrenal cancers in adults ENS@T-CANCERparticipant5.993.97816
2011-01-01EUROPEAN NETWORK for CANCER research in CHILDREN and ADOLESCENTS ENCCAparticipant11.997.95934
2011-01-01Predicting individual response and resistance to VEGFR/mTOR pathway therapeutic intervention using biomarkers discovered through tumour functional genomics PREDICTparticipant5.841.00914
2011-01-01A European Platform for Translational Cancer Research EUROCANPLATFORMparticipant11.998.45428

Alias institution names:

  • INSTITUT GUSTAVE ROUSSY